Search
forLearn
5 / 801 resultslearn 18β-glycyrrhetinic acid
learn β-Glycyrrhetinic Acid
learn Ceramide AP
learn Ceramide A2
Research
5 / 1000+ results
research Mechanisms of hepatocyte attachment to keratin biomaterials
Human liver cells stick to hair protein materials mainly through the liver's asialoglycoprotein receptor.
research 851 The role of astrotactin2 in regulating mammalian skin polarity
Astrotactin2 affects hair follicle orientation and skin cell polarity.
research Efficient In Vitro Transfection of Human Keratinocytes with an Adenovirus-Enhanced Receptor-Mediated System
The AVET system effectively delivers genes to human keratinocytes and may help treat skin diseases.
research Follikelhormone
Follicle Stimulating Hormone is important for fertility.
research Changes in the Hydrophobic Proteins in Response to Biotin Administration in Serum of Infant Patients with Alopecia as Assessed by the Protein Micro-Sequencing Method
Biotin helps regulate proteins in the blood, which may explain its role in hair growth.
Community Join
5 / 1000+ resultscommunity ASATONA AG and "Asatex"
The conversation discusses Melatonin's potential benefits for AGA and a product called "Asatex" by ASATONA AG. The company was uncooperative when contacted for purchase inquiries.
community Patent for topical resveratrol and melatonin for AGA
The conversation discusses a patent for using topical resveratrol and melatonin to treat androgenetic alopecia (AGA) and also mentions interest in topical sulforaphane as a treatment.
community Best Treatment In The Pipeline?
New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.
community Spanish dermatologist suggests sulforaphane for AGA
A Spanish dermatologist suggests sulforaphane for androgenetic alopecia (AGA) due to its potential to remove DHT metabolites, though high dosages are needed. A topical formulation might be possible.
community AH-001 another topical AR degrader beside GT20029, completed Phase I
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.